An open label multi facilities cooperation randomized control trial for prevention Evolution of Diabetic nephrOpathy by Olmesartan

An open label multi facilities cooperation randomized control trial for prevention Evolution of Diabetic nephrOpathy by Olmesartan - Olmesartan prevents Evolution of Diabetic nephrOpathy(OEDO-STUDY)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002718

Enrollment

120

Registered

2009-11-09

Start date

2011-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive type2 diabetic patients without nephropathy

Interventions

olmesartan10-40mg once a day for six months amlodipine 2.5-10mg once a day for six months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hypertensive type2 diabetic patients without nephropathy Outpatients aged 20 years or moreover SBP is >= 130mgHg or DBP is >= 80mgHg Type2 diabetes Albuminuria is below 30mg/gCr Untreated hypertensive patients or patients treated with CaB alone Agreement

Exclusion criteria

Exclusion criteria: SBP >=160mgHg or DBP >=100mgHg. Secondary hypertension Severe hepatic dysfunction or renal damage. Severe adverse effects with study drugs. Severs clincal condition due to tumors et al. Inappropriate cases based on the descision by responsible doctors .

Design outcomes

Primary

Measure	Time frame
an incrase of albuminuria	—

Secondary

Measure	Time frame
1) number of patients with above 30mg/gCr albuminuria 2) an increase of urinary L-PGDS excretions	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026